Radionucleotide imaging due diligence


A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.


Alacrita’s expert imaging consultant reviewed the clinical evidence generated to date and provided an opinion as to whether the technology’s performance could displace existing methodologies and standard of care in the USA. We suggested that the commercial hurdles were higher than the target company was proposing and, as a result, our client did not proceed with the deal.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch